When to start cholesterol-lowering therapy in patients with coronary heart disease. A statement for healthcare professionals from the American Heart Association task force on risk reduction

Circulation

Volumn 95, Issue 6, 1997, Pages 1683-1685

  Grundy, Scott M ^a   Balady, Gary J ^a   Criqui, Michael H ^a   Fletcher, Gerald ^a   Greenland, Philip ^a   Hiratzka, Loren F ^a   Houston Miller, Nancy ^a   Kris Etherton, Penny ^a   Krumholz, Harlan M ^a   LaRosa, John ^a   Ockene, Ira S ^a   Pearson, Thomas A ^a   Reed, James ^a   Smith Jr , Sidney C ^a   Washington, Reginald ^a  

^a NONE

Author keywords

AHA Medical Scientific Statements; cholesterol; diet; drugs; prevention

Indexed keywords

LOW DENSITY LIPOPROTEIN CHOLESTEROL; SIMVASTATIN;

ARTICLE; ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CORONARY ARTERY BYPASS GRAFT; HEALTH CARE; HUMAN; ISCHEMIC HEART DISEASE; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK FACTOR;

EID: 16944366070     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.95.6.1683     Document Type: Article

References (20)

1. National Cholesterol Education Program: Second Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). Circulation. 1994;89:1333-1445.
2. Rossouw JE, Lewis B, Rifkind BM. The value of lowering cholesterol after myocardial infarction. N Engl J Med. 1990;323:1112-1119.
3. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383-1389.
4. Byington RP, Jukema JW, Salonen JT, Pitt B, Bruschke AV, Hoen H, Furberg CD, Mancini GB. Reduction in cardiovascular events during pravastatin therapy: pooled analysis of clinical events of the Pravastatin Atherosclerosis Intervention Program. Circulation. 1995;92:2419-2425.
5. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JMO, Wun C-C, Davis BR, Braunwald E, for the Cholesterol and Recurrent Events Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 1996;335:1001-1009.
6. Buchwald H, Varco RL, Matts JP, Long JM, Fitch LL, Campbell GS, Pearce MB, Yellin AE, Edmiston WA, Smink RD Jr, Sawin HS, Campos CT, Hansen BJ, Tune N, Karnegis JN, Sanmarco ME, Amplatz K, Castaneda-Zuniga WR, Hunter DW, Bissett JK, Weber FJ, Stevenson JW, Leon AS, Chalmers TC, the POSCH group. Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia: report of the Program on the Surgical Control of Hyperlipidemias (POSCH). N Engl J Med. 1990;323:946-955.
7. Brown BG, Zhao X-Q, Sacco DE, Albers JJ. Lipid lowering and plaque regression: new insights into prevention of plaque disruption and clinical events in coronary disease. Circulation. 1993;87:1781-1791.
8. The Post Coronary Artery Bypass Graft Trial Investigators. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. N Engl J Med. 1997;336:153-162.
9. Smith SC Jr, Blair SN, Criqui MH, Fletcher GF, Fuster V, Gersh BJ, Gotto AM, Gould KL, Greenland P, Grundy SM, Hill MM, Hlatky MA, Houston-Miller N, Krauss RM, LaRosa J, Ockene IS, Oparil S, Pearson TA, Rapaport E, Starke RD, the Secondary Prevention Panel. Preventing heart attack and death in patients with coronary disease. Circulation. 1995;92:2-4.
10. 27th Bethesda Conference: Matching the Intensity of Risk Factor Management With the Hazard for Coronary Disease Events; September 14-15, 1995. J Am Coll Cardiol. 1996;27:957-1047.
11. LaRosa JC. Guidelines for detection and treatment of dyslipoproteinemia in adults. In: Rifkind BM, ed. Drug Treatment of Hyperlipidemia. New York, NY: Marcel Dekker; 1991:58.
12. Gore JM, Goldberg RJ, Matsumoto AS, Castelli WP, McNamara PM, Dalen JE. Validity of serum total cholesterol level obtained within 24 hours of acute myocardial infarction. Am J Cardiol. 1984;54:722-725.
13. Ahnve S, Angelin B, Edhag O, Berglund L. Early determination of serum lipids and apolipoproteins in acute myocardial infarction: possibility for immediate intervention. J Intern Med. 1989;226:297-301.
14. Carlsson R, Lindberg G, Westin L, Israelsson B. Serum lipids four weeks after acute myocardial infarction are a valid basis for lipid lowering intervention in patients receiving thrombolysis. Br Heart J. 1995;74:18-20.
15. Caggiula AW, Watson JE, Kuller LH, Olson MB, Milas NC, Berry M, Germanowski J. Cholesterol-lowering intervention program: effect of the step I diet in community office practices. Arch Intern Med. 1996;156:1205-1213.
16. Pearson T, Rapaport E, Criqui M, Furberg C, Fuster V, Hiratzka L, Little W, Ockene I, Williams G. Optimal risk factor management in the patient after coronary revascularization: a statement for healthcare professionals from an American Heart Association Writing Group. Circulation. 1994;90:3125-3133.
17. The Lipid Research Clinics Coronary Primary Prevention Trial results, I: reduction in incidence of coronary heart disease. JAMA. 1984;251:351-364.
18. The Lipid Research Clinics Coronary Primary Prevention Trial results, II: the relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA. 1984;251:365-374.
19. Clofibrate and niacin in coronary heart disease. JAMA. 1975;231:360-381.
20. Oberman A, Kreisberg RA, Henkin Y. Principles and Management of Lipid Disorders: A Primary Care Approach. Baltimore, Md: Williams & Wilkins; 1992:256.